

# pSELECT-NHis-blasti

Plasmid for the expression of polyhistidine (His)-N-terminal tagged proteins

Catalog code: psetb-nhis

<https://www.invivogen.com/pselect-his-tag>

For research use only

Version 20117-MM

## PRODUCT INFORMATION

### Contents

- 20 µg of pSELECT-NHis-blasti plasmid provided as lyophilized DNA
- 2 x 1 ml blasticidin at 10 mg/ml

### Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store blasticidin at 4°C or -20°C. The expiry date is specified on the product label.

### Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

## GENERAL PRODUCT USE

pSELECT plasmids are specifically designed for strong and constitutive expression of a gene of interest in a wide variety of cell lines. They allow the selection of stable transfectants and offer a variety of selectable markers. pSELECT plasmids contain two expression cassettes: the first drives the expression of the gene of interest and the second drives the expression of a large choice of dominant selectable markers for both *E. coli* and mammalian cells. They are both terminating with a strong polyadenylation signal (polyA) that separates the two expression cassettes thus preventing any transcription interference. The late SV40 polyA terminates the transcription of the gene of interest while the human β-globin polyA terminates the transcription of the selectable marker.

pSELECT-Tag is a new family of expression plasmids designed to generate tagged proteins in order to facilitate their detection and/or purification. pSELECT-Tag features three well-known tags: the green fluorescent protein (GFP) gene, the human influenza hemagglutinin (HA) epitope and the polyhistidine (His) tag. pSELECT-Tag plasmids allow to add the tag either at the N or C terminus of the protein of interest. The N-terminal tag: the tag encompasses the Start codon and is followed by a multiple cloning site (MCS).

## PLASMID FEATURES

### First expression cassette

- **hEF1-HTLV prom** is a composite promoter comprising the Elongation Factor-1α (EF-1α) core promoter<sup>1</sup> and the R segment and part of the U5 sequence (R-U5') of the Human T-Cell Leukemia Virus (HTLV) Type 1 Long Terminal Repeat<sup>2</sup>. The EF-1α promoter exhibits a strong activity and yields long lasting expression of a transgene *in vivo*. The R-U5' has been coupled to the EF-1α core promoter to enhance stability of RNA.
- **MCS:** The multiple cloning site contains the following restriction sites: 5' - Age I, Sal I, Eco47 III, Nco I, BamH I - 3' Each restriction site is compatible with many other enzymes.

- **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA<sup>3</sup>.

- **ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

### Second expression cassette

- **CMV enh/prom:** The human cytomegalovirus immediate-early gene 1 promoter/enhancer was originally isolated from the Towne strain and was found to be stronger than any other viral promoters.

- **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.

- **Blasti:** Resistance to Blasticidin S is conferred by the *bsr* gene from *Bacillus cereus*. The *bsr* gene is driven by the CMV enhancer/promoter in tandem with the bacterial EM7 promoter allowing selection in both mammalian cells and *E. coli*.

- **βGlo pAn:** The human beta-globin 3'UTR and polyadenylation sequence allows efficient arrest of the transgene transcription<sup>4</sup>.


## CLONING STRATEGY

For expression of a tagged protein, it is important to ensure to clone your gene-of-interest into the correct reading frame. In general it is recommended to use BamHI/NheI restriction site combination for cloning into plasmids with the N-Tag. For the plasmids with N-Tag, check whether your gene of interest and the start codon of the N-tag are in the correct reading frame.

Note: The Bam HI restriction site is compatible with BgIII.



If it is not possible to use the NheI restriction site, it is possible to use another restriction site such as NcoI.



Alternatively, blunt end cloning can be achieved using the Eco47III site, which is downstream of the BamHI site. Blunt end PCR fragments can be obtained using T4 DNA polymerase or Klenow.



## TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: [info@invivogen.com](mailto:info@invivogen.com)

## METHODS

### Plasmid resuspension

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H<sub>2</sub>O. Store resuspended plasmid at -20°C.

### Plasmid amplification and cloning

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

### Blasticidin usage

Blasticidin should be used at 25-100 µg/ml in bacteria and 1-30 µg/ml in mammalian cells. Blasticidin is supplied at 10 mg/ml in HEPES buffer.

### References:


1. Kim, D.W. et al., 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. *Gene* 2: 217-223. 2. Takebe, Y. et al., 1988. SR alpha promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. *Mol. Cell Biol.* 1: 466-472. 3. Carswell, S., & Alwine, J.C., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol. Cell Biol.* 10: 4248-4258. 4. Yu J & Russell JE., 2001. Structural and functional analysis of an mRNP complex that mediates the high stability of human beta-globin mRNA. *Mol Cell Biol.* 21(17):5879-88.

## RELATED PRODUCTS

Product	Catalog Code
pSELECT-NGFP-blasti	psetb-ngfp
pSELECT-CGFP-blasti	psetb-cgfp
pSELECT-NGFP-zeo	psetz-ngfp
pSELECT-CGFP-zeo	psetz-cgfp
pSELECT-NHA-blasti	psetb-nha
pSELECT-CHA-blasti	psetb-cha
pSELECT-NHA-zeo	psetz-nha
pSELECT-CHA-zeo	psetz-cha
pSELECT-NHis-zeo	psetz-nhis
pSELECT-CHis-blasti	psetb-chis

### TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873  
InvivoGen USA (International): +1 (858) 457-5873  
InvivoGen Europe: +33 (0) 5-62-71-69-39  
InvivoGen Hong Kong: +852 3622-3480  
E-mail: [info@invivogen.com](mailto:info@invivogen.com)



**NotI (-1)**

1 GCGGCCGCAATAAAATATCTTTATTTTCATTACATCTGTGTGTTGGTTTTTTGTGTGAATCGTAACTAAC  
71 ATACGCTCTCCATCAAAACAAAACGAAACAAAACAACTAGCAAAATAGGCTGTCCCCAGTGCAAGTGCA  
141 GGTGCCAGAACATTTCTCTATCGAAGGATCTGCGATCGCTCCGGTGCCCGTCAGTGGGCAGAGCGCACAT

211 CGCCACAGTCCCCGAGAAGTTGGGGGAGGGGTCGGCAATTGAACGGGTGCCTAGAGAAGGTGGCGCGG

281 GGTAACCTGGGAAAGTGATGTCGTGTACTGGCTCCGCTTTTTCCCGAGGGTGGGGGAGAACCGTATATA

**HindIII (410)**

351 AGTGCAGTAGTCGCCGTGAACGTTCTTTTTCGCAACGGGTTTGCCGCCAGAACACAGCTGAAGCTTCGAG

421 GGGCTCGCATCTCTCCTTCACGCGCCCGCCGCTACCTGAGGCCGCCATCCACGCCGGTTGAGTCGCGT

491 TCTGCCGCTCCCGCCTGTGGTGCCTCCTGAACTGCGTCCGCCGTCTAGGTAAGTTTAAAGCTCAGGTCCG

561 AGACCGGGCCTTTGTCCGGCGCTCCCTTGAGCCTACCTAGACTCAGCCGGCTCTCCACGCTTTGCCTGA

631 CCCTGCTTGCTCAACTCTACGTCTTTGTTTCGTTTTCTGTTCTGCGCCGTTACAGATCCAAGCTGTGACC

**BspHI (725)**

**Eco47III (763)**

**AgeI (717)**

**BamHI (757)**

701 GCGCGCTACCTGAGATCACCGGTCATCATGAGCGGCTCCCATCATCATCACCATCACGGATCCAGCGCTG

1 MetSer Gl ySer Hi sHi sHi sHi sHi sHi sGl ySer

**NheI (779)**

**NcoI (773)**

771 CAGCCATGGGCTAGCTGGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACCTAGAATGC

841 AGTGAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAA

911 TAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTTCAAGGGGAGGTGTGGGAGGTTTTT

**EcoRI (1013)**

981 TAAAGCAAGTAAACCTCTACAAATGTGGTATGGAATTCTAAAATACAGCATAGCAAACTTTAACCTCC

1051 AAATCAAGCCTCTACTTGAATCCTTTTCTGAGGGATGAATAAGGCATAGGCATCAGGGGCTGTTGCCAAT

1121 GTGCATTAGCTGTTTGCAGCCTCACCTTCTTTTCATGGAGTTTAAAGATATAGTGTATTTTCCCAAGGTTTG

1191 AACTAGCTCTTCATTTCTTTATGTTTTAAATGCACTGACCTCCCACATTCCCTTTTTAGTAAAATATTCA

1261 GAAATAATTTAATACATCATTGCAATGAAAATAAATGTTTTTTATTAGGCAGAATCCAGATGCTCAAGG

1331 CCCTTCATAATATCCCCAGTTTAGTAGTTGACTTAGGGAACAAAGGAACCTTTAATAGAAATTGGACA

1401 GCAAGAAAGCGAGCTTCTAGCTTTAGTTCCTGGTGTACTTGAGGGGGATGAGTTCCTCAATGGTGGTTTT

141 •••AsnArgThr TyrLysLeuP roI l eLeuGl uGl uI l eThr Thr Lys

1471 GACCAGCTTGCCATTCATCTCAATGAGCACAAAGCAGTCAGGAGCATAGTCAGAGATGAGCTCTCTGCAC

125 Val LeuLysGl yAsnMetGl uI l eLeuVal PheCysAspP roAl aTyrAspSer I l eLeuGl uArgCysM

1541 ATGCCACAGGGGCTGACCACCCTGATGGATCTGTCCACCTCATCAGAGTAGGGGTGCTGACAGCCACAA

101 etGl yCysProSer Val ValArgI l eSerArgAspVal Gl uAspSer TyrProHi sArgValAl aVal I l

1611 TGGTGTCAAAGTCTTCTGCCGTTGCTCACAGCAGACCAATGGCAATGGCTTCAGCACAGACAGTGAC

78 eThrAspPheAspLysGl nGl yAsnSer ValAl aSer Gl yI l eAl aI l eAl aGl uAl aCysVal Thr Val

1681 CCTGCCAATGTAGGCCTCAATGTGGACAGCAGAGATGATCTCCCAGTCTTGGTCTGATGGCCGCCCG

55 ArgGl yI l eTyrAl aGl uI l eHi sValAl aSer I l eI l eGl uGl yThr LysThrArgI l eAl aAl aGl yV

1751 ACATGGTGCTTGTTGCCTCATAGAGCATGGTGATCTTCTCAGTGGCGACCTCCACCAGCTCCAGATCCT

31↓ a l H i s H i s L y s A s n A s p G l u T y r L e u M e t T h r I l e L y s G l u T h r A l a V a l G l u V a l L e u G l u L e u A s p G l

BspHI (1841)

1821 GCTGAGAGATGTTGAAGGCTTTCATGATGGCCCTCCTATAGTGAGTCGTATTATACTATGCCGATATACT

8↓ n G l n S e r I l e A s n P h e T h r L y s M e t

AseI (1899)

1891 ATGCCGATGATTAATTGTCAAACAGCGTGGATGGCGTCTCCAGCTTATCTGACGGTTCACTAAACGAGC

1961 TCTGCTTATATAGACCTCCCACCGTACACGCCTACCGCCATTTGCGTCAATGGGGCGGAGTTGTTACGA

SpeI (2054)

2031 CATT T T T G G A A A G T C C C G T T G A T T T A C T A G T C A A A A C A A A C T C C C A T T G A C G T C A A T G G G G T G G A G A C T T

2100 G G A A T C C C C G T G A G T C A A A C C G C T A T C C A C G C C A T T G A T G T A C T G C C A A A A C C G C A T C A T C A T G G T A A

2170 T A G C G A T G A C T A A T A C G T A G A T G T A C T G C C A A G T A G G A A A G T C C C A T A A G G T C A T G T A C T G G G C A T A A T G

2240 C C A G G C G G G C A T T T A C C G T C A T T G A C G T C A A T A G G G G G C G T A C T T G G C A T A T G A T A C A C T T G A T G T A C T

2310 G C C A A G T G G G C A G T T T A C C G T A A A T A C T C C A C C C A T T G A C G T C A A T G G A A A G T C C C T A T T G G C G T T A C T A

2380 T G G G A A C A T A C G T C A T T A T T G A C G T C A A T G G G C G G G G T C G T T G G G C G G T C A G C C A G G C G G G C A T T T A C

PacI (2473)

SdaI (2465)

2450 C G T A A G T T A T G T A A C G C C T G C A G G T T A A T T A A G A A C A T G T G A G C A A A A G G C C A G C A A A A G G C C A G G A A

2518 C C G T A A A A A G G C C G C G T T G C T G G C G T T T T T C C A T A G G C T C C G C C C C C T G A C G A G C A T C A C A A A A T C G A

2588 C G C T C A A G T C A G A G G T G G C G A A A C C C G A C A G G A C T A T A A A G A T A C C A G G C G T T T C C C C C T G G A A G C T C C C

2658 T C G T G C G C T C T C C T G T T C C G A C C C T G C C G C T T A C C G G A T A C C T G T C C G C C T T T C T C C C T T C G G G A A G C G T

2728 G G C G C T T T C T C A T A G C T C A C G C T G T A G G T A T C T C A G T T C G G T G T A G G T C G T T C G C T C C A A G C T G G G C T G T

ApaLI (2797)

2798 G T G C A C G A A C C C C C G T T C A G C C C G A C C G C T G C G C C T T A T C C G G T A A C T A T C G T C T T G A G T C C A A C C C G G

2868 T A A G A C A C G A C T T A T C G C C A C T G G C A G C A G C C A C T G G T A A C A G G A T T A G C A G A G C G A G G T A T G T A G G C G G

2938 T G C T A C A G A G T T C T T G A A G T G G T G G C C T A A C T A C G G C T A C A C T A G A A G A A C A G T A T T T G G T A T C T G C G C T

3008 C T G C T G A A G C C A G T T A C C T T C G G A A A A A G A G T T G G T A G C T C T T G A T C C G G C A A A C A A A C C A C C G C T G G T A

3078 G C G G T G G T T T T T T T G T T T G C A A G C A G C A G A T T A C G C G C A G A A A A A A A G G A T C T C A A G A A G A T C C T T T G A T

PacI (3213)

3148 C T T T T C T A C G G G G T C T G A C G C T C A G T G G A A C G A A A A C T C A C G T T A A G G G A T T T T G G T C A T G G C T A G T T A A

3218 T T A A C A T T T A A A T C A